INCY vs IONS vs LLY vs ALNY vs REGN

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Incyte Corporation is actually cheaper at 13. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 0. 98x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to +18. 2% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: LLY returned +1238% versus INCY's +34. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 55β versus Incyte Corporation's 0. 87β — meaning INCY is approximately 60% more volatile than IONS relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 0. 98x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Incyte Corporation (INCY) trades at 13. 1x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 31. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.

In this comparison, LLY (0.

6% yield), REGN (0. 5% yield) pay a dividend. INCY, IONS, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Both have compounded well over 10 years (LLY: +1238%, INCY: +34. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INCY is a mid-cap high-growth stock; IONS is a mid-cap high-growth stock; LLY is a large-cap high-growth stock; ALNY is a mid-cap high-growth stock; REGN is a mid-cap deep-value stock. LLY pays a dividend while INCY, IONS, ALNY, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.